Think10

www.Think-10.com is a life science business consultancy, a personal coaching and team development to all businesses and a service to the pharmaceutical industry to facilitate change,

Melanie Lee PhD, CBE, FMedSci, DSc(Hons)

LifeArc

Chief Executive Officer

Principal CEO

BTGplc

BTG plc is a fast growing exciting Interventional Medicine company - on the international stage with it's HQ in London. We have device and drug combination products in the Interventional vascular and oncology space and have recently entered the Interventional Pulmonary area with the acquisition of PneuMRx and their innovative coiled device to treat emphysema patients. Interventional medicine routes to the market place in the hands of skilled physicians is likely to be relevant to many of the emerging new modalities in the pipelines of our innovative biotechs today.

Chief Scientific Officer

NightstaRx Ltd

NightstaRx is a Syncona backed company established to pursue the gene therapy treatment of Choroideremia to prevent the deterioration of eyesight in patients with this X-linked disease which causes loss of sight during the mid 40-50 years of life. Early clinical studies by Robert MacLaren have shown promising efficacy and good safety. The therapy for this indication is to replace the faulty REP1 gene in the eye with a functioning copy in an AAV vector. NightstaRx aims to gain regulatory approval for this therapy with ensuring GMP of the product and agreeing the pivotal clinical path. Www.nightstarx.co.uk

NED (was Founding CEO during 2014)

Syntaxin Ltd

Syntaxin was a successful biotech spun out of the HPA that was developed by myself and my management team, with the help if course of our excellent scientists, to a stage for acquisition to ensure the further investment in the recombinant botulinum toxin technology. Ipsen acquired Syntaxin in July 2013 and the site continues as Ipsen's centre for toxin engineering, complementing well the Ipsen expertise in toxin biology. I left Syntaxin with the acquisition and now work through Think10 as I discuss new opportunities.

Chief Executive officer

EVP and President UCB NewMedicines

Breast Cancer Haven

Angel

Applied Genomics Link Scheme

Working to award funds to innovate collaborative programmes between strong academic groups and small companies.

Chairman

Celltech

EVP R&D, Celltech

Glaxo

Unit Head

I'm a passionate leader dedicated to driving innovation and positive impact in the life sciences industry.🔬

Throughout my career, I have championed the translation of scientific knowledge into impactful healthcare solutions and am passionate about fostering an environment that encourages multidisciplinary collaboration, nurtures scientific talent, and supports the next generation of innovators.

I actively engage with industry leaders, policymakers, and research institutions to shape the future of the life sciences ecosystem.

By participating in conferences, thought leadership activities, and industry forums, I strive to drive positive change and advance the boundaries of medical research.

I am always excited to speak with like-minded professionals, researchers, and individuals passionate about making a difference in healthcare. ⬇️

Let's amplify our impact in healthcare by connecting and collaborating towards a brighter future.🧑🏻‍🔬

Melanie Lee

Epilepsy Society

Board Trustee

Accountable for setting LifeArc’s portfolio strategy in line with charitable objectives and delivering the portfolio through effective project leadership and management. Develop and lead the Translational Challenges as a core element of strategy; these programmes accelerate healthcare innovation by transforming promising life science ideas into life-changing medical breakthroughs for patients. They consider the entire patient pathway – from diagnosis through to treatment and lifestyle support in complex areas of healthcare need. LifeArc provides translational insight, spanning our core offerings of science, funding and advice and connect these collective strengths and resources with the expertise, capabilities and funding of other life sciences partners to catalyse the translation of innovation.

Chief Project and Portfolio Officer

Accountable for LifeArc’s Translational Challenges to accelerate healthcare innovation by transforming promising life science ideas into life-changing medical breakthroughs for patients.

Head of Translational Challenges

Accountable for ensuring effective governance, processes, systems and resource are applied across the entire company including our scientific research programmes, IT improvements, strategic and infrastructure, together with those utilising LifeArc’s offerings of advice and funds.
Developing and implementing strategy, translating LifeArc’s strategic ambitions into well-crafted and achievable operational plans, managing the portfolios, ensuring focus on the highest-level company priorities. Leading major change initiatives to support integration of emerging technologies and adapting operating model design for delivery and agility.

Head of Corporate and Portfolio Project Management

Accountable for building and maintaining productive collaborative relationships with major research partners. Managing the Tech Transfer of antibody technology platforms into LifeArc (transgenic mice, B cell sorting and screening, and in silico bioinformatics for candidate selection) ensuring all facilities, equipment and resources in place to optimise use for therapeutic discovery.

Consultant, Alliance Manager

KQ Labs

Accelerator programme run by the Francis Crick Institute, supporting innovative early-stage data-driven health start-ups to validate their ideas and put their exciting companies on the path to receive further investment.

Governance Board Member

PIPMG

The aim of PIPMG is to support development of the Project Management profession in the global pharmaceutical, biotech and associated industries by:
1. Encouraging recognition of the key role of project management in the industry
2. Enabling learning and sharing of best practices in portfolio, programme and project management
3. Providing Training, Coaching and Continual Professional Development
4. Providing a forum for communication and information exchange between members
5. Introduction, participation in and support of initiatives intended to improve the practice of project management internationally

Executive Committee Member

BTG plc

Global Head of Immuno-Oncology 
Accountable for the strategic direction and commercial success of our Immuno-Oncology platform, managing collaborative partnerships with global pharmaceutical companies, leading research institutions and societies. 
Lead a broad portfolio of pre-clinical and clinical research projects investigating the ability of our interventional oncology therapies (selective internal radiation, ablation solutions, embolics) to drive immune responses, both alone and in combination with immunotherapeutics (check point inhibitors, next generation immunotherapies).

VP Immuno-Oncology

Head of Global Project Management organisation  
Managed R&D governance process, annual portfolio review, and business analytics to track and improve performance, prioritising budget and resource on a risk-balanced pipeline of R&D projects that maximise business value.

VP Project Management

Head of Global Project Management organisation 
Line management of a global team (US, EU, APAC), set project management vision and strategy, ensuring effective project management resource, processes and systems applied across the business, with high standards for delivery.

Group Manager of Project Management

Clinical lead of multiple out-sourced clinical trials with small molecules, peptides, biologics and medical devices (spanning Phase I, II, III and IV).

Clinical Development Executive

Merck

Directed exploratory neuroscience research project teams, selecting multiple candidates for clinical development using pre-clinical models.

Research Manager

Directed learning and memory disorder program, heading GABA α5 inverse agonist pre-clinical research project for the treatment of mild cognitive impairment and Alzheimer’s disease.

Project Director

Headed an exploratory research team of technical personnel running electrophysiological assays for Neuroscience disorders (CHO cell lines, Xenopus oocytes, mouse brain slices) for structure-activity relationship assessment of novel small molecules and drug candidate prioritisation.

Team Leader

Conducted exploratory research, characterising the pharmacology of tachykinin receptors in the brain (nucleus tractus solitarius, dorsal motor nucleus of the vagus, amygdala, entorhinal cortex).

Senior Research Biologist

Karen Skinner is Chief Project & Portfolio Officer at the medical research organisation, LifeArc with accountability for their portfolio of Translational Challenges. These ambitious programmes focus primarily on Rare Disease (including ultra-rare diseases, MND and rare dementias, rare respiratory conditions and childhood cancer), and Global Health. In addition to her role at LifeArc, Karen is a Board Trustee of the Epilepsy Society and member of PIPMG Executive team. 

She has over 30 years of experience within the life sciences industry, having held numerous leadership roles in blue chip big pharma, specialty pharma, biotech and nonprofit organisations. 
She is passionate about biomedical science and technology, applying that knowledge to create innovative products that make a real difference for patients. She believes that collaboration is the key to accelerate the progress of scientific discoveries to create medical breakthroughs that transform the lives of those living with disease. 

Life Sciences | Director | Transformational Leader | Portfolio Management | Keynote Speaker

taplio

The Battle

Melanie Lee

Karen Skinner

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?